One of the strategies for the treatment of RA is to convert traditional Treg cells into Foxp3+ Treg cells with stable inhibitory function, and reduce the related inflammation caused by the conversion of Treg cells into Th17 cells (199, 200). The gene discussed is FOXP3; the disease is rheumatoid arthritis.